BIO Asia–Taiwan 2025 亞洲生技大會

BIO Asia–Taiwan 2025 亞洲生技大會

PROGRAM

2025 Satellite Symposia

​​

Jul.24

Next-Generation Approaches in Drug Development

Room 402C, Hall 1

Date / Time :July 24 14:00-17:00
Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 402C)
Co-organizer: LumiSTAR Biotechnology, Molecular Devices

Time Topic Speaker
14:00-14:10 Opening Remarks & Group Photo Woolen Pan
14:10-14:45 Modernizing Drug Discovery: Innovative Human iPSC-Derived 3D Models as Animal Testing Alternatives Yu-Fen Chang
CEO and founder, LumiSTAR Biotechnology
14:45-15:20 Designing Microenvironments and Nanosurfaces for Controlling iPSCs and Their Application in Drug Screening and Regenerative Medicine Li Liu
CTO, EngiTissue Design
15:20-15:40 Tea Break & Networking  
15:40-16:15 Building Better Brain Drugs: Key Considerations in Early CNS Drug Discovery Elsa Liu
Technical Director, Eurofins Panlabs Discovery Services Taiwan
16:15-16:50 Leveraging High-Throughput Screening in Biomedical Research: From Principles to Practice Ting-Jen Cheng
16:50-17:00 Closing Remarks Yu-Fen Chang 
CEO and founder, LumiSTAR Biotechnology
Session Synopsis:
Join us for an illuminating symposium exploring the forefront of drug discovery innovation. This session brings together leading experts to showcase how cutting-edge human iPSC-derived 3D models, engineered microenvironments, and high-throughput screening technologies are transforming the landscape of biomedical research and therapeutic development.
Discover how advances in stem cell biology are enabling animal-free drug testing, in line with the FDA Modernization Act 2.0. Learn about the latest breakthroughs in designing nanosurfaces and microenvironments for precise control of iPSCs, and their applications in both drug screening and regenerative medicine. Gain insights into the unique challenges and opportunities in early CNS drug discovery, and see how high-throughput screening is accelerating research from principle to practice.
Whether you are a scientist, product manager, or industry leader, this session will provide actionable knowledge and a holistic perspective on the next generation of drug discovery tools and strategies.
 

Jul.24

Treg Symposium 2025
Engineering Immune Peace: Translating Treg Science into Clinical Reality

Room 403, Hall 1

Register

Date / Time : July 24 08:00-17:00

Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 403)

Co-organizer : Taiwan Bio Therapeutics INC.

Time Topic Speaker
08:00-08:30 Registration  
08:30-09:00 Opening Remarks Session Chair: Cyrus Yang
09:00-10:00 Discovery of New Immunotherapy Targets and Mechanisms Leveraging CRISPR Arlene H. Sharpe
Kolokotrones University Professor|Harvard Medical School
10:00-10:30 Coffee Break  
10:30-11:30 Tfr Regulation of Antibody Mediated Diseases Peter T. Sage
Associate Professor of Medicine|Harvard Medical School and Brigham and Women's Hospital
11:30-13:00 Lunch Break  
13:00-14:00 Therapy in Autoimmunity with a Focus on Inflammatory Bowel Disease William A. Faubion
Dean of Research, MCA|Mayo Clinic 
Executive Medical Director, CRB|Mayo Clinic
14:00-15:00 Polymeric Particles for Immunomodulation Jordan J. Green
Herschel L. Seder Professor of Biomedical Engineering|Johns Hopkins University School of Medicine
15:00-15:20 Coffee Break  
15:20-16:20 Industry Perspective: Polyclonal Regulatory T Cell Therapy 
in Solid Organ Transplantation Clinical Trials

Cyrus Yang
CEO|Taiwan Bio Therapeutics INC.

16:20-17:00 Panel Discussion & Concluding Remarks Moderator: Cyrus Yang
Panelists: Arlene H. Sharpe, Peter T. Sage, William A. Faubion, Jordan J. Green
Session Synopsis:
Regulatory T cells (Tregs) have long been recognized as central mediators of immune tolerance. What distinguishes the current moment in the field is the maturity of science and technology, which now makes it possible to translate decades of discovery into real therapeutic opportunities. With growing momentum in clinical trials and the advent of genetic engineering to enhance Treg stability, specificity, and function, Treg-based therapies are rapidly evolving from concept to clinic—offering new hope for patients with autoimmune diseases and for preventing transplant rejection.
Treg Symposium 2025 offers a timely and focused platform to explore these advances. By bringing together leading experts from both academia and industry, the symposium fosters the kind of interdisciplinary dialogue essential for addressing the scientific, clinical, and manufacturing challenges of Treg therapy. Topics will span from cutting-edge tools for understanding Treg biology and discovering new therapeutic opportunities, to clinical-stage developments of ex vivo Treg therapies and emerging strategies for in vivo Treg modulation.

Jul.24

Promega Session-Innovating Biologics: Accelerating Drug Discovery and Development with Functional Bioassays

Room 503, Hall 1

Register

Date / Time : July 24 13:00–17:30

Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 503)

Co-organizer : Promega Corporation

Time Topic Speaker
13:00-13:30

Registration

 
13:30

Opening

LayPing Lee
Director, Sales & Marketing
Promega Corporation, Singapore

13:35-14:20

Illuminating Biologics Drug Discovery with Innovative Assays

Dr. Frank Fan
Head of Biology, R&D
Promega Corporation, U.S.A

14:20-15:20

The Bioluminescent Toolbox for Vaccine Characterization and mRNA Quality Control

Dr. Jamison Grailer
Senior Research Scientist
Promega Corporation, U.S.A

15:20-15:50

Promega Bioassays: Enabling Reliable Methodology for Research and Industrial Advancement

Dr. Mei-Wei Lin
Manager
Industrial Technology Research Institute

15:50-16:00

Break

 
16:00-16:30

Bioassays Development for Product Release and Characterization - From a CDMO Perspective

Dr. Toby Hong
Associate Director of Analytical/Formulation Development & Cell Line/Cell Culture Process Development
Bora Biologics

16:30-17:20

Bioluminescent Platform Technologies for Functional Characterization of Advanced Cancer Therapeutics

Dr. Jamison Grailer
Senior Research Scientist
Promega Corporation, U.S.A

17:20

Closing

Dr. Frank Fan
Head of Biology, R&D
Promega Corporation, U.S.A

Jul.25

AI for Bio-Pharma Integrated Practice of Design, Quality, and Manufacturing

Room 402AB, Hall 1

Register

Date / Time : July 25 14:00-17:00

Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 402AB)
Co-organizer: Genetics Generation Advancement Corp, Taiwan Bio Industry Organization

Time Topic Speaker
14:00-14:30

Guest Registration

 
14:30-14:45

Opening Remarks

 

14:45-15:15

Session 1 –Harnessing AI to Decode Bio Signatures: A New Frontier in Precision Drug Development

Tsai, Keng-Chang Professor
National Research Institute Of Chinese Medicine
Dr. Andrew Pai 
Principal Scientist, AnnJi Pharmaceutical

Lucas Nivon
CEO, Cyrus Biotechnology

15:15-15:45

Session 2 – Accelerating Drug Innovation and Lab Automation through AI

Peng Hua
BIOVIA Industry Process Consultant, Dassault Systèmes
Wayne Chang
Chairman, Lightest Biomedical Co., Ltd.

15:45-15:50

Q&A

 

15:50-16:10

Session 3 – Leveraging AI-Driven Process Optimization to Transform Biopharmaceutical Manufacturing

 

Jack Lim
Regional Account Executive, Asia Pacific, MasterControl

16:10-17:00

AI Demo Time

 

Session Synopsis:
As the global AI era unfolds, artificial intelligence is rapidly transforming the biopharmaceutical landscape—from drug design and quality control to manufacturing processes. This forum, themed “AI for Bio-Pharma Integrated Practice of Design, Quality, and Manufacturing”, will spotlight the multifaceted applications and successful use cases of AI in the biopharmaceutical industry.
We are honored to bring together leading experts from both Taiwan and abroad, including representatives from the National Research Institute Of Chinese Medicine, Dassault Systèmes, and MasterControl. Together, they will explore how AI is becoming a critical driving force in the industry, unlocking new potential and future opportunities.
The forum will feature three key topics:
Harnessing AI to Decode Bio Signatures: A New Frontier in Precision Drug Development 
Accelerating Drug Innovation and Lab Automation through AI: Enhancing pharmaceutical quality management and process innovation
Leveraging AI-Driven Process Optimization to Transform Biopharmaceutical Manufacturing: How electronic batch records are reshaping manufacturing and quality systems
On behalf of the Bionet Group, we sincerely invite professionals from pharmaceutical companies, biotech firms, CRDMOs, and academic research institutions to join us for this insightful event.

Jul.25

Breaking into the U.S. Healthcare Innovation Market

Room 404, Hall 1


 

Jul.25

Digital and Automated Cell Manufacturing: From QbD to AI and Robotics

Room 503, Hall 1

Register

Date / Time : July 25 13:30–17:00

Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 503)

Co-organizer : Purple Win Co., Ltd.

Time Topic Speaker
13:30–14:00

Registration

 
14:00–14:10

Opening Remarks

Session Chair
14:10–15:10

Advanced Morphological AI Analysis as a Process Analytical Technology for Quality by Design–Driven Process Development

Ryuji Kato

Associate Professor, Nagoya University, Tokai National Higher Education and Research System
15:10–15:30

Coffee Break

 
15:30–15:40

2nd Opening Remark

 
15:40–16:40

Development of robotic automation system for cell manufacturing

Masahiro Kino-oka

Professor, Department of Biotechnology, The University of Osaka
16:40–17:00

Closing Discussion

 

Jul.26

Colon Cancer Symposium 2025

Room 401, Hall 1

Register

Date / Time : July 26 09:00–12:00

Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 401)

Co-organizer : Taiwan Biomedical Innovation Association, Taiwan Bio Industry Organization, NHRI Institute of Population Health Sciences
Language: Chinese only

Time Topic Speaker
09:00-09:20

Registration

 
09:20-09:25

Opening Remarks

Dr. Yun Yen
Chairman, Taiwan Biomedical Innovation Association
09:25-09:30

Special Address

Dr. Huey-Herng Sheu
Deputy President, National Health Research Institutes

 

09:30-09:35 Group Photo  
09:35-10:00

Global trend of colorectal cancer by age, gender and risk factors

Dr. Hung-Yi Chiou
Director, NHRI Institute of Population Health Sciences
10:00-10:25

Diabetes mellitus/hyperglycemia on colorectal cancer risk and oncological outcomes: from basic studies to clinical perspectives

Dr. Jaw-Yuan Wang
Superintendent, Kaohsiung Medical University Chung-Ho Memorial Hospital

 

10:25-10:40

Coffee Break

 
10:40-11:05 Evolution and Execution of Colorectal Treatment Dr. Po-Li Wei
Superintendent, Taipei Cancer Center, Taipei Medical University
11:05-11:30 Ovulation may promote carcinogenesis in the proximal colon Dr. Tang-Yuan Chu
Director, Center for Prevention and Therapy of Gynecological Cancers, Hualien Tzuchi General Hospital
11:30-11:50 Panel Discussion Moderator: Dr. Yun Yen
Panelists:
Dr. Hung-Yi Chiou
Dr. Jaw-Yuan Wang
Dr. Po-Li Wei
Dr. Tang-Yuan Chu
11:50-12:00 Kulia Labs' Demo Winn Hong
CEO, Kulia Labs
12:00- Closing Remarks Dr. Yun Yen
Chairman, Taiwan Biomedical Innovation Association
Session Synopsis:
There are no obvious symptoms in the early stages of colorectal cancer, and it is associated with a variety of risk factors, including unhealthy diet, lack of exercise, smoking, intestinal inflammation, environmental factors, and genetics. In particular, the trend of younger women causing concern. This seminar will bring together experts and scholars to discuss the phenomenon of younger colorectal cancer, gender differences, risk factors, and coping strategies, and hopes to raise public awareness of this issue, promote early screening and preventive measures, thereby reducing the risk of younger cancers and protecting the health of future generations.